The ALS Association, Harvard Stem Cell Institute, and Massachusetts General … – PR Newswire (press release)
|
The ALS Association, Harvard Stem Cell Institute, and Massachusetts General …
PR Newswire (press release) The trial will evaluate the potential of the drug, Retigabine, which has a unique mechanism of action and can calm the excitability of nerve cells that are thought to cause seizures. These "hyperexcitable neurons" are also thought to play a role in ALS. |
